ArticleScientific reports2025
Study of epinephrine-induced cardiovascular adverse events in patients with anaphylaxis using two spontaneously reported adverse event databases from 2004 to 2024.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis is a life-threatening hypersensitivity reaction requiring prompt administration of epinephrine. Despite its life-saving role, hesitancy in epinephrine use persists, largely due to concerns about cardiovascular adverse events (AEs). This study aimed to characterize potentially epinephrine-induced cardiovascular AEs in anaphylaxis using data from two major pharmacovigilance databases. A retrospective analysis was conducted using individual case safety reports (ICSRs) from the US FDA Adverse Event Reporting System (FAERS) and the European EudraVigilance database from 2004 to 2024. ICSRs were included if epinephrine was a suspect drug and the indication involved anaphylaxis or related terms. Reports were screened for cardiovascular AEs and assessed for causality by two independent reviewers. Descriptive statistics were used to summarize findings. A total of 802 and 517 ICSRs were analyzed from FAERS and EudraVigilance, respectively. Cardiovascular AEs were reported in 142 and 134 ICSRs, respectively, with epinephrine as the sole suspect in most cases. Female patients were more frequently represented. Stress cardiomyopathy, myocardial ischemia, tachycardia, and acute myocardial infarction were the most common cardiovascular AEs. Intravenous administration was frequently associated with serious outcomes. Causality assessment indicated that a majority of cardiovascular AEs were likely related to epinephrine. Cardiovascular AEs, particularly stress cardiomyopathy, are associated with epinephrine use in anaphylaxis, especially when administered intravenously. While these findings support cautious use, they also highlight the importance of adhering to recommended intramuscular administration to minimize preventable risks. Clinician awareness and adherence to guidelines remain critical for safe and effective anaphylaxis management, prioritizing cautious use over hesitancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.